Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haleh Saber

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Regulatory Toxicology and Pharmacology : RTP|February 10, 2015
An FDA oncology analysis of antibody-drug conjugatesHaleh Saber, John K Leighton
Regulatory Toxicology and Pharmacology : RTP|April 1, 2024
Pharmacokinetic models for first-in-human dose selection of immune-activating products in oncologyHaleh Saber, Matthew D Thompson, John K Leighton
Regulatory Toxicology and Pharmacology : RTP|March 9, 2016
An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugsJohn K Leighton, Haleh Saber, Gregory Reaman, et al.
JAMA|April 20, 2026
Eliminating Unnecessary Animal TestingTracy Beth Høeg, Steven Kozlowski, Haleh Saber, et al.
Regulatory Toxicology and Pharmacology : RTP|July 21, 2019
An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugatesHaleh Saber, Natalie Simpson, Tiffany K Ricks, et al.
Regulatory Toxicology and Pharmacology : RTP|October 17, 2016
An FDA oncology analysis of immune activating products and first-in-human dose selectionHaleh Saber, Ramadevi Gudi, Michael Manning, et al.
Regulatory Toxicology and Pharmacology : RTP|September 10, 2017
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selectionHaleh Saber, Pedro Del Valle, Tiffany K Ricks, et al.
International Journal of Radiation Oncology, Biology, Physics|June 8, 2017
Clinical Development of Cancer Drugs in Combination With External Beam Radiation Therapy: US Food and Drug Administration PerspectiveAmanda J Walker, Hyun Kim, Haleh Saber, et al.
Regulatory Toxicology and Pharmacology : RTP|November 4, 2019
An FDA analysis of clinical hold deficiencies affecting investigational new drug applications for oncology productsMichael L Manning, Matthew D Thompson, Haleh Saber, et al.
Oncology|June 10, 2010
FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantationMichael Brave, Ann Farrell, Sue Ching Lin, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Regulatory Toxicology and Pharmacology : RTP|February 10, 2015
An FDA oncology analysis of antibody-drug conjugatesHaleh Saber, John K Leighton
Regulatory Toxicology and Pharmacology : RTP|April 1, 2024
Pharmacokinetic models for first-in-human dose selection of immune-activating products in oncologyHaleh Saber, Matthew D Thompson, John K Leighton
Regulatory Toxicology and Pharmacology : RTP|March 9, 2016
An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugsJohn K Leighton, Haleh Saber, Gregory Reaman, et al.
JAMA|April 20, 2026
Eliminating Unnecessary Animal TestingTracy Beth Høeg, Steven Kozlowski, Haleh Saber, et al.
Regulatory Toxicology and Pharmacology : RTP|July 21, 2019
An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugatesHaleh Saber, Natalie Simpson, Tiffany K Ricks, et al.
Regulatory Toxicology and Pharmacology : RTP|October 17, 2016
An FDA oncology analysis of immune activating products and first-in-human dose selectionHaleh Saber, Ramadevi Gudi, Michael Manning, et al.
Regulatory Toxicology and Pharmacology : RTP|September 10, 2017
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selectionHaleh Saber, Pedro Del Valle, Tiffany K Ricks, et al.
International Journal of Radiation Oncology, Biology, Physics|June 8, 2017
Clinical Development of Cancer Drugs in Combination With External Beam Radiation Therapy: US Food and Drug Administration PerspectiveAmanda J Walker, Hyun Kim, Haleh Saber, et al.
Regulatory Toxicology and Pharmacology : RTP|November 4, 2019
An FDA analysis of clinical hold deficiencies affecting investigational new drug applications for oncology productsMichael L Manning, Matthew D Thompson, Haleh Saber, et al.
Oncology|June 10, 2010
FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantationMichael Brave, Ann Farrell, Sue Ching Lin, et al.
Pageof 3